Generic Medicine Info
Cardiogenic shock, pre-existing 2nd- or 3rd-degree heart block w/o pacemaker, bundle branch block associated w/ 1st-degree AV block, congenital QT prolongation, severe sick sinus syndrome. Concomitant use w/ TCAs, tetracyclic antidepressants, macrolide antibiotics, and other drugs that may increase risk of torsade de pointes. Renal (CrCl ≤40 mL/min) impairment (modified-release).
Special Precautions
Patient w/ AF/flutter, benign prostatic hyperplasia, electrolyte imbalance (i.e. hypokalaemia, hypomagnesaemia), glaucoma, uncompensated CHF (unless secondary to cardiac arrhythmia), cardiomyopathy, myasthenia gravis, Wolff-Parkinson-White syndrome. Elderly. Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor ECG, BP, disopyramide drug level, and serum K and blood sugar levels.
Adverse Reactions
Significant: QT interval prolongation, QRS complex widening, AV bock, bundle branch block, hypotension, severe heart failure, cardiogenic shock. Nervous: Nervousness, headache, dizziness. CV: Oedema, chest pain, bradycardia, sinus block, ventricular fibrillation, ventricular tachycardia. GI: Dry mouth, abdominal pain, nausea, vomiting, anorexia, diarrhoea, constipation. Resp: Dyspnoea. Hepatic: Cholestatic jaundice, elevated liver enzymes. Genitourinary: Dysuria, acute urinary retention, frequency, and urgency. Endocrine: Hypoglycaemia. Haematologic: Thrombocytopenia, agranulocytosis, neutropenia. Ophthalmologic: Diplopia. Otic: Blurred vision. Dermatologic: Rash. Others: Wt gain.
Potentially Fatal: Torsades de pointes.
Drug Interactions
Enhanced QT prolongation effect w/ phosphodiesterase type 5 inhibitors. Increased serum levels if concomitantly used w/ CYP3A4 enzyme inhibitors (e.g. azole antifungals). Reduced serum levels w/ CYP3A4 enzyme inducers (e.g. rifampicin, phenytoin). May cause competitive inhibition of metabolism w/ HIV protease inhibitors (e.g. ritonavir, indinavir, saquinavir), ciclosporin, warfarin, and theophylline. May induce hypokalaemia or potentiate proarrhythmic effects when used w/ diuretics, amphotericin B, gluco- and mineralo-corticoids, laxatives. Potentiate atropine-like effects when used w/ atropine and other anticholinergic agents (e.g. phenothiazines).
CIMS Class
Cardiac Drugs
ATC Classification
C01BA03 - disopyramide ; Belongs to class Ia antiarrhythmics.
Disclaimer: This information is independently developed by CIMS based on disopyramide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in